1 RES-0001 selec-w TEN-0001 tenders 1 CON-0001 LOT-0001 TEN-0001 1 no TPA-0001 LOT-0001 HSE 27864 CON-0001 HSE 27864 TEN-0001 TPA-0001 Sanofi Aventis Ireland Ltd ORG-0004 29 https://www.hse.ie ORG-0001 Health Service Executive (HSE) Oak House, Millennium Park Naas Co. Kildare HSE Kildare RE IE062 IRL 0043024G 087 1893120 procurement.helpdesk@hse.ie ORG-0002 The High Court of Ireland Four Courts, Inns Quay, Dublin 7 The High Court of Ireland Dublin D07 WDX8 IE061 IRL The High Court of Ireland +353 1 8886000 HighCourtCentralOffice@courts.ie ORG-0003 European Dynamics S.A. European Dynamics S.A. Athens 15125 EL301 GRC 002024901000 +30 2108094500 eproc-esender@eurodyn.com large ORG-0004 Sanofi Aventis Ireland Ltd Sanofi Aventis Ireland Ltd Dublin Dublin 24 IE061 IRL 166500 00676444-2026190/20262026-10-01+02:00 2.3 eforms-sdk-1.13 34ca1ef2-9605-4f21-a758-0b107407b32e 78754bbd-e24a-40c9-b90d-336fbd35c0b4 2026-09-30+01:00 12:11:14+01:00 01 32014L0024 can-standard ENG https://www.hse.ie body-pl health ORG-0001 ted-esen ORG-0003 neg-wo-call technical There is only one sole supplier of monoclonal antibody approved that has received EMA authorisation. National Contract for Monoclonal Antibody for Respiratory Syncytial Virus (RSV) Passive Immunisation for Infants - Pathfinder Programme 3 In accordance with National Immunisation Advisory Committee (NIAC) advice, HSE Public Health: National Health Protection, with Access & Integration and the National Women and Infants Health Programme wish to put in place a contract for a monoclonal antibody, Nirsevimab (Beyfontus®) for a third pathfinder immunisation programme to protect all babies from RSV disease born from 1st March 2026 to 28th February 2027. RSV is a common virus that causes respiratory infections in young babies. Babies under three months old get sicker with RSV than older children. Each winter in Ireland one in two newborns babies will get RSV and many will need medical care from their GP or the emergency department of a children’s hospital. Four out of a hundred new born babies are hospitalised due to RSV with some babies needing special treatment in intensive care units. Nirsevimab is currently the best way to protect babies from RSV. This contract will supply 50,000 doses of this drug for passive immunisation over a seven month period during the RSV season. supplies 1 33651600 IE061 IRL LOT-0001 false no-eu-funds Negotiated with sole authorised supplier Negotiated cost Negotiated cost Negotiated with sole authorised supplier ORG-0002 ORG-0002 false false none none 1 National Contract for Monoclonal Antibody for Respiratory Syncytial Virus (RSV) Passive Immunisation for Infants - Pathfinder Programme 3 In accordance with National Immunisation Advisory Committee (NIAC) advice, HSE Public Health: National Health Protection, with Access & Integration and the National Women and Infants Health Programme wish to put in place a contract for a monoclonal antibody, Nirsevimab (Beyfontus®) for a third pathfinder immunisation programme to protect all babies from RSV disease born from 1st March 2026 to 28th February 2027. RSV is a common virus that causes respiratory infections in young babies. Babies under three months old get sicker with RSV than older children. Each winter in Ireland one in two newborns babies will get RSV and many will need medical care from their GP or the emergency department of a children’s hospital. Four out of a hundred new born babies are hospitalised due to RSV with some babies needing special treatment in intensive care units. Nirsevimab is currently the best way to protect babies from RSV. This contract will supply 50,000 doses of this drug for passive immunisation over a seven month period during the RSV season. supplies none 1 33651600 IE061 IRL 2026-09-30+01:00